A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Stopped AstraZeneca has decided to stop further enrollment and the study was terminated when all patients in Part 1 completed their last study visit. No safety issues or clinical concerns however, have been identified for this study. Part 2 was not initiated

Conditions

• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer

Interventions

• DRUG: Durvalumab
• DRUG: Cisplatin
• DRUG: Carboplatin
• DRUG: Etoposide

Sponsor

AstraZeneca